Researchers from the Murdoch Children’s Research Institute (MCRI) and biotech company Organovo have successfully bio-printed miniature human kidneys with unparalleled speed and quality to be used for toxicity screening of medications known to cause kidney damage.
A world leader in modeling the kidney, Professor Melissa Little of the MRCI said, “Drug-induced injury to the kidney is a major side effect and difficult to predict using animal studies. Bioprinting human kidneys are a practical approach to testing for toxicity before use.”
The new study involved testing the toxicity of aminoglycosides, a class of antibiotics that commonly damage the kidney. The study revealed deaths of certain types of kidney cells when exposed to aminoglycosides.
Organovo first began bio-printing kidneys in 2015, but their new processes are much faster, allowing 200 mini-kidneys to be produced in 10 minutes. The improvement in speed and quality has opened the doorway for bioprinting entire organs for transplant. “3-D bioprinting can generate larger amounts of kidney tissue but with precise manipulation of biophysical properties, including cell number and conformation, improving the outcome.”
Professor Little said that prior to this study, the possibility of using such technology for transplantation was too complicated to consider. “The pathway to renal replacement therapy using stem cell-derived kidney tissue will need a massive increase in the number of nephron structures present in the tissue to be transplanted,” she said.
“By using extrusion bioprinting, we improved the final nephron count, which will ultimately determine whether we can transplant these tissues into people.”
Source: Medical Xpress
